Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Repligen Conference: CEO touts differentiated bioprocessing portfolio; CFO targets 30% EBITDA margin

Summary by marketbeat.com
Repligen (NASDAQ:RGEN) executives outlined a strategy focused on portfolio breadth, innovation, and commercial execution during a recent discussion with Life Science Analyst Paul Knight. Chief Executive Officer Olivier said he has been with the company about two and a half years and has served as CE

1 Articles

marketbeat.commarketbeat.com
Center

Repligen Conference: CEO touts differentiated bioprocessing portfolio; CFO targets 30% EBITDA margin

Repligen (NASDAQ:RGEN) executives outlined a strategy focused on portfolio breadth, innovation, and commercial execution during a recent discussion with Life Science Analyst Paul Knight. Chief Executive Officer Olivier said he has been with the company about two and a half years and has served as CE

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

marketbeat.com broke the news in on Sunday, March 22, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

CFO icon

CFO

Innovation icon

Innovation

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal